A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study

A.K.L. Reyners; L. de Munck; F.L.G. Erdkamp; W.M. Smit; K. Hoekman; R.I. Lalisang; H. de Graaf; A.N.M. Wymenga; M. Polee; H Hollema; M.A.T.M. van Vugt; M. Schaapveld; P.H.B. Willemse

doi:10.1093/annonc/mds107

A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study

A.K.L. Reyners, L. de Munck, F.L.G. Erdkamp, W.M. Smit, K. Hoekman, R.I. Lalisang, H. de Graaf, A.N.M. Wymenga, M. Polee, H Hollema, M.A.T.M. van Vugt, M. Schaapveld, P.H.B. Willemse

Medical oncology

Research output: Contribution to journal › Article › Academic › peer-review

Original language	Undefined/Unknown
Pages (from-to)	2896-2902
Journal	Annals of Oncology
Volume	23
Issue number	11
DOIs	https://doi.org/10.1093/annonc/mds107
Publication status	Published - 2012

Access to Document

10.1093/annonc/mds107

Cite this

Reyners, A. K. L., de Munck, L., Erdkamp, F. L. G., Smit, W. M., Hoekman, K., Lalisang, R. I., de Graaf, H., Wymenga, A. N. M., Polee, M., Hollema, H., van Vugt, M. A. T. M., Schaapveld, M., & Willemse, P. H. B. (2012). A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study. Annals of Oncology, 23(11), 2896-2902. https://doi.org/10.1093/annonc/mds107

Reyners, A.K.L. ; de Munck, L. ; Erdkamp, F.L.G. et al. / A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study. In: Annals of Oncology. 2012 ; Vol. 23, No. 11. pp. 2896-2902.

@article{a2e76bedc2534bbbb09f0a5a49d621a4,

title = "A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study",

author = "A.K.L. Reyners and {de Munck}, L. and F.L.G. Erdkamp and W.M. Smit and K. Hoekman and R.I. Lalisang and {de Graaf}, H. and A.N.M. Wymenga and M. Polee and H Hollema and {van Vugt}, M.A.T.M. and M. Schaapveld and P.H.B. Willemse",

year = "2012",

doi = "10.1093/annonc/mds107",

language = "Undefined/Unknown",

volume = "23",

pages = "2896--2902",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

number = "11",

}

Reyners, AKL, de Munck, L, Erdkamp, FLG, Smit, WM, Hoekman, K, Lalisang, RI, de Graaf, H, Wymenga, ANM, Polee, M, Hollema, H, van Vugt, MATM, Schaapveld, M & Willemse, PHB 2012, 'A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study', Annals of Oncology, vol. 23, no. 11, pp. 2896-2902. https://doi.org/10.1093/annonc/mds107

A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study. / Reyners, A.K.L.; de Munck, L.; Erdkamp, F.L.G. et al.

In: Annals of Oncology, Vol. 23, No. 11, 2012, p. 2896-2902.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study

AU - Reyners, A.K.L.

AU - de Munck, L.

AU - Erdkamp, F.L.G.

AU - Smit, W.M.

AU - Hoekman, K.

AU - Lalisang, R.I.

AU - de Graaf, H.

AU - Wymenga, A.N.M.

AU - Polee, M.

AU - Hollema, H

AU - van Vugt, M.A.T.M.

AU - Schaapveld, M.

AU - Willemse, P.H.B.

PY - 2012

Y1 - 2012

U2 - 10.1093/annonc/mds107

DO - 10.1093/annonc/mds107

M3 - Article

C2 - 22689176

SN - 0923-7534

VL - 23

SP - 2896

EP - 2902

JO - Annals of Oncology

JF - Annals of Oncology

IS - 11

ER -

Reyners AKL, de Munck L, Erdkamp FLG, Smit WM, Hoekman K, Lalisang RI et al. A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study. Annals of Oncology. 2012;23(11):2896-2902. doi: 10.1093/annonc/mds107